---
title: Omalizumab for the Treatment of Multiple Food Allergies
date: '2024-02-26'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38407394/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240227170500&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In persons as young as 1 year of age with multiple food
  allergies, omalizumab treatment for 16 weeks was superior to placebo in increasing
  the reaction threshold for peanut and other common food allergens. (Funded by the
  National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov
  number, ...'
disable_comments: true
---
CONCLUSIONS: In persons as young as 1 year of age with multiple food allergies, omalizumab treatment for 16 weeks was superior to placebo in increasing the reaction threshold for peanut and other common food allergens. (Funded by the National Institute of Allergy and Infectious Diseases and others; ClinicalTrials.gov number, ...